Tecotabart vedotin clinical trials
Also written LM-302.
How each study uses tecotabart vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tecotabart vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 5
LaNova Medicines Zhejiang Co., Ltd. (3) · Ruijin Hospital (3) · Shanghai Zhongshan Hospital (2) · LaNova Australia Pty Limited (1) · Turning Point Therapeutics, Inc. (1) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (1)
Often tested with
Tested in the same studies.
Tegafur (2) · Gimeracil (2) · Oxonic Acid (2) · Paclitaxel (2) · Cadonilimab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test tecotabart vedotin, phase 3 first.
- Nov 2026LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.Phase 3 · LaNova Medicines Zhejiang Co., Ltd.
- Jan 2027Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal MetastasisPhase 2 · Ruijin Hospital
Studies
Open first, then newest update. How each study uses tecotabart vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as LM-302
- Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal MetastasisRecruitingPhase 2Ruijin HospitalNCT06519591Written as Cadonilimab, LM-302, S-1, paclitaxel
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingPhase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07385703Written as LM-302 Injection
- Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ AdenocarcinomaRecruitingPhase 2Ruijin HospitalNCT07569068Written as Tislelizumab, LM-302 and S-1
- LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory StudyRecruitingPhase 2Ruijin HospitalNCT07556640Written as LM-302, S-1, paclitaxel
- Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic CancerNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07108504Written as LM-302
- Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 AntibodyActive, not recruitingPhase 1/2Shanghai Zhongshan HospitalNCT05994001Written as LM-302
- LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.Active, not recruitingPhase 3LaNova Medicines Zhejiang Co., Ltd.NCT06351020Written as LM-302
- Study of LM-302 in Patients With Advance Solid TumorsCompletedPhase 1/2LaNova Medicines Zhejiang Co., Ltd.NCT05161390Written as LM-302 Injection
- Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid TumorsCompletedPhase 1/2LaNova Australia Pty LimitedNCT05188664Written as LM-302
- Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid TumorsCompletedPhase 1Turning Point Therapeutics, Inc.NCT05001516Written as LM-302
Codes
What other systems call tecotabart vedotin · ClinicalTrials.gg INT015866
- UNII (FDA) 9GK5GYD8DQTECOTABART VEDOTINOne source FDA
- NCI Thesaurus C185853Tecotabart VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9GK5GYD8DQ | TECOTABART VEDOTIN | One source FDA |
| NCI Thesaurus | C185853 | Tecotabart Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.